Neoadjuvant immunotherapy improves outcomes for resectable gastroesophageal junction cancer: A systematic review and meta‐analysis
Cancer Medicine · 2024-05 · 13 (9)
DOI: 10.1002/cam4.7176 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Cancer Medicine, online erschienen am 08.05.2024. Verfasst von Danzhu Wu und 9 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Medical College of Jining Medical University, Jining, Shandong Province, China. Hauptthemen laut MEDLINE: Neoadjuvant Therapy, Esophagogastric Junction, Esophageal Neoplasms, Stomach Neoplasms. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 57 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Clinical Research Fund of Shandong Medical Association-Qilu Special Project, Bethune-Cancer Radiotherapy Translational Medicine Research Fund.
Abstract (Originalsprache)
Background
In recent years, neoadjuvant immunotherapy (NAIT) has developed rapidly in patients with gastroesophageal junction cancer (GEJC). The suggested neoadjuvant treatment regimens for patients with GEJC may vary in light of the efficacy and safety results.
Methods
A search of the Cochrane Library, PubMed, Embase, and Web of Science was completed to locate studies examining the safety and effectiveness of NAIT for resectable GEJC. We analyzed the effect sizes (ES) and 95% confidence intervals (CI) in addition to subgroups and heterogeneity. Meta‐analyses were performed using Stata BE17 software.
Results
For these meta‐analyses, 753 patients were chosen from 21 studies. The effectiveness of NAIT was assessed using the pathological complete response (pCR), major pathological response (MPR), and nodal downstage to ypN0 rate. The MPR, pCR, and nodal downstage to ypN0 rate values in NAIT were noticeably higher (MPR: ES = 0.45; 95% CI: 0.36–0.54; pCR: ES = 0.26; 95% CI: 0.21–0.32; nodal downstage to ypN0 rate: ES = 0.60; 95% CI: 0.48–0.72) than those of neoadjuvant chemotherapy (nCT) or neoadjuvant chemoradiotherapy (nCRT) (MPR < 30%; pCR: ES = 3%–17%; nodal downstage to ypN0 rate: ES = 21%–29%). Safety was assessed using the treatment‐related adverse events (trAEs) incidence rate, surgical delay rate, surgical complications incidence rate, and surgical resection rate. In conclusion, the incidence of trAEs, incidence of surgical complications, and surgical delay rate had ES values of 0.66, 0.48, and 0.09, respectively. These rates were comparable to those from nCT or nCRT (95% CI: 0.60–0.70; 0.15–0.51; and 0, respectively). The reported resection rates of 85%–95% with nCT or nCRT were comparable to the mean surgical resection rate of 90%.
Conclusion
NAIT is an effective treatment for resectable GEJC; additionally, the level of NAIT toxicity is acceptable. The long‐term effects of NAIT require further study.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Clinical Medical College of Jining Medical University, Jining, Shandong Province, China.
- Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China.
- Department of General Surgery, Shandong Provincial Qianfoshan Hospital, Cheeloo College of Medicine, Shandong University, Jinan, China.
- Department of Oncology, The Second Affiliated Hospital of Shandong First Medical University and Shandong Provincial Qianfoshan Hospital, Taian, Jinan, Shandong, China.
- Department of Oncology, The First Affiliated Hospital of Shandong First Medical University and Shandong Provincial Qianfoshan Hospital, Shandong Key Laboratory of Rheumatic Disease and Translational Medicine, Shandong L…
- Medical College, Wuhan University of Science and Technology, Wuhan, China.
ORCID-Profile: Xinshuang Yu
Förderung
- Clinical Research Fund of Shandong Medical Association-Qilu Special Project
- Bethune-Cancer Radiotherapy Translational Medicine Research Fund
Zitieren
APA
Wu, D., Yang, L., Yan, Y., Jiang, Z., Liu, Y., Dong, P., Lv, Y., Zhou, S., Qiu, Y., & Yu, X. (2024). Neoadjuvant immunotherapy improves outcomes for resectable gastroesophageal junction cancer: A systematic review and meta‐analysis. Cancer Medicine, 13(9). https://doi.org/10.1002/cam4.7176
Vancouver
Wu D, Yang L, Yan Y, Jiang Z, Liu Y, Dong P, et al. Neoadjuvant immunotherapy improves outcomes for resectable gastroesophageal junction cancer: A systematic review and meta‐analysis. Cancer Medicine. 2024;13(9). doi:10.1002/cam4.7176
BibTeX
@article{Wu2024,
author = {Wu, Danzhu and Yang, Liyuan and Yan, Yu and Jiang, Zhengchen and Liu, Yinglong and Dong, Peng and Lv, Yajuan and Zhou, Siqin and Qiu, Yiyang and Yu, Xinshuang},
title = {Neoadjuvant immunotherapy improves outcomes for resectable gastroesophageal junction cancer: A systematic review and meta‐analysis},
journal = {Cancer Medicine},
year = {2024},
volume = {13},
number = {9},
doi = {10.1002/cam4.7176}
}
EUVIMED